Chugai Seiyaku Kabushiki Kaisha

University College London

Masaaki Kosaka

Yasuo Koishihara

Masayuki Tsuchiya

Toshihiko Ohtomo

Yuji Wakahara

Shuji Ozaki

Koichiro Ono

Yasushi Yoshimura

Shigeto Kawai

Yasuo Koishibara

Yong Kwee

Yasuo Chugai Seiyaku Kabushiki Kaisha Koishihara

Toshihiko Chugai Seiyaku Kabushiki Kaisha Ohtomo

Koichiro Chugai Seiyaku Kabushiki Kaisha Ono

An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon &#x3b1;, interferon &#x3b3;, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.

Therapeutic agent for hematopoietic tumors

A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide or transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA.

HM1.24&#x2014;utilizing cancer vaccines

An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-&#x3b1; or interferon-&#x3b3;, or IRF-2 protein as an active ingredient. Interferon-&#x3b1; or interferon-&#x3b3; is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen.

Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen

An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon &#x3b1;, interferon &#x3b3;, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.

The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.

Reshaped human anti-HM 1.24 antibody

An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active ingredient.

Enhancer for antibody to lymphocytic tumors

There are provided a genomic DNA comprising 4 exons encoding the amino acid sequence as set forth in SEQ ID NO: 2 and 3 introns ligating them, and a splicing variant of said genomic DNA; as well as a DNA having the base sequence as set forth in SEQ ID NO: 4 and a promoter activity and the fragment thereof, and uses thereof.

Gene encoding HM1.24 antigen protein and promoter thereof

A method of detecting or determining plasmacytoma cells in a sample, said method comprising amplifying a polynucleotide that is specifically or strongly expressed in said plasmacytoma cells, and then detecting or measuring the amplified product.

Growing community of inventors

Tokushima, Japan

Masaaki Kosaka